Genotypic and phenotypic analysis of the polymorphic thiopurine S‐methyltransferase gene (TPMT) in a European population
- 1 October 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 125 (4) , 879-887
- https://doi.org/10.1038/sj.bjp.0702152
Abstract
1. Characterization of allelic variants of the TPMT gene (TPMT) responsible for changes in TPMT activity, and elucidation of the mechanism by which these alleles act, are required because of the clinical importance of this polymorphism for patients receiving thiopurine drugs. 2. We defined the mutational and allelic spectrum of TPMT in a group of 191 Europeans. Using PCR-SSCP, we screened for mutation the entire coding sequence, the exon-intron boundaries, the promoter region and the 3'-flanking region of the gene. Six mutations were detected throughout the ten exons and seven TPMT alleles were characterized. Four of them, TPMT*2, *3A, *3C and *7, harbouring the known mutations, G238C, G460A, A719G or T681G, were nonfunctional and accounted for 0.5, 5.7, 0.8 and 0.3% of the allele totality, respectively. 3. Within the promoter region, six alleles corresponding to a variable number of tandem repeats (VNTR), were identified. VNTR*V4 and *V5a which harbour four or five repeats of a 17-18 bp unit, were the most frequent (55% and 34%, respectively). The other VNTR alleles, having from five to eight repeats, were rarer. 4. The TPMT phenotype was correctly predicted by genotyping for 87% of individuals. A clear negative correlation between the total number of repeats from both alleles and the TPMT activity level was observed, indicating that VNTRs contribute to interindividual variations of TPMT activity. Therefore, additional analysis of the promoter region of TPMT can improve the phenotype prediction rate by genotyping.Keywords
This publication has 36 references indexed in Scilit:
- Pharmacokinetics, dose adjustments, and 6‐mercaptopurine/ methotrexate drug interactions in two patients with thiopurine methyltransferase deficiencyActa Paediatrica, 1998
- Possibilities for Therapeutic Drug Monitoring of AzathioprineTherapeutic Drug Monitoring, 1997
- Erythrocyte thiopurine methyltransferase activity in a Korean populationBritish Journal of Clinical Pharmacology, 1996
- Erythrocyte thiopurine methyltransferase activity in a Korean populationBritish Journal of Clinical Pharmacology, 1996
- Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanismsPharmacogenetics, 1996
- Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adultsPharmacogenetics, 1995
- Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.Archives of Disease in Childhood, 1993
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990